China-Coronavirus/Sinovac

Sinovac's COVID-19 vaccine 91.25 percent effective in Turkey trials: CEO

  • English
  • Français

Shotlist


Beijing, China - Jan 13, 2021 (CCTV - No access Chinese mainland)
1. Press conference
2. Reporters
3. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd. (starting with shot 2):
"This vaccine entered Phase I and Phase II clinical studies in April 2020. After confirming the safety and efficacy of the vaccine, we started Phase III clinical studies in Brazil, Turkey, Indonesia, Chile and other countries."
4. Reporters
5. Government officials at press conference
6. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd (partially overlaid with shot 7):
"We have enrolled 24,400 volunteers, finished the overall evaluation work and released the main research data. The interim analysis results for the trials in Turkey showed the vaccine is 91.25 percent effective. The results of Phase III clinical trials in Indonesia showed the vaccine has an efficacy rate of 64.5 percent."
++SHOT OVERLAYING SOUNDBITE++
7. Reporters
++SHOT OVERLAYING SOUNDBITE++
8. Various of reporters
9. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd:
"The Phase III trials in Brazil showed the vaccine is 100 percent effective in preventing severe illness and hospitalization. It is 78 percent effective in preventing medical treatment, and 50.3 percent effective for high-risk groups such as medical workers."

Beijing, China - Recent (CCTV - No access Chinese mainland)
10. Various of Sinovac Biotech workers at workshop, vaccines on producing line

Beijing, China - Jan 13, 2021 (CCTV - No access Chinese mainland)
11. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd:
"As of January 10, more than 7 million doses of inactivated vaccines have been supplied to different provincial-level regions in China, especially Beijing and Guangdong, where large-scale vaccinations have been started, showing good safety of the vaccine. We are still studying and tracking the efficacy rate for the Chinese recipients."

Shanghai, China - Jan 6, 2021 (CCTV - No access Chinese mainland)
12. Various of medical worker registering vaccine recipients' information
13. Medical worker injecting COVID-19 vaccine on man

Beijing, China - Jan 2-6, 2021 (CCTV - No access Chinese mainland)
14. People lining up for vaccination

Shanghai, China - Jan 6, 2021 (CCTV - No access Chinese mainland)
15. Medical worker injecting COVID-19 vaccine on man

Storyline


The coronavirus vaccine developed by China's Sinovac Biotech is 91.25 percent effective in its Phase III clinical trials in Turkey, Board Chairman and CEO of the company Yin Weidong said in Beijing on Wednesday.

"This vaccine entered Phase I and Phase II clinical studies in April 2020. After confirming the safety and efficacy of the vaccine, we started Phase III clinical studies in Brazil, Turkey, Indonesia, Chile and other countries," Yin said at a press conference.

Yin said the company has finished the overall evaluation of the Phase III trials after enrolling the test results of 24,400 volunteers.

"The interim analysis results for the trials in Turkey showed the vaccine is 91.25 percent effective. The results of Phase III clinical trials in Indonesia showed the vaccine has an efficacy rate of 64.5 percent," he said.

"The Phase III trials in Brazil showed the vaccine is 100 percent effective in preventing severe illness and hospitalization. It is 78 percent effective in preventing medical treatment, and 50.3 percent effective for high-risk groups such as medical workers," said Yin.

He said the vaccine is being widely administered among Chinese citizens.

"As of January 10, more than 7 million doses of inactivated vaccines have been supplied to different provincial-level regions in China, especially Beijing and Guangdong, where large-scale vaccinations have been started, showing good safety of the vaccine. We are still studying and tracking the efficacy rate for the Chinese recipients," Yin said.

DOWNLOAD
  • ID : 8173471
  • Dateline : Jan 13, 2021/File
  • Location : Beijing,China
  • Category : health
  • Duration : 2'37
  • Audio Language : Chinese/Nats
  • Source : China Central Television (CCTV)
  • Restrictions : No access Chinese mainland
  • Published : 2021-01-13 17:58
  • Last Modified : 2021-01-14 15:58:45
  • Version : 2
  • ID : 8173471
  • Dateline : 13 janv. 2021/Archives
  • Location : Beijing,Chine
  • Category : health
  • Duration : 2'37
  • Audio Language : Chinois/Nats
  • Source : China Central Television (CCTV)
  • Restrictions : Pas d’accès dans la partie continentale de Chine
  • Published : 2021-01-13 21:05
  • Last Modified : 2021-01-14 15:58:45
  • Version : 2

China-Coronavirus/Sinovac

Sinovac's COVID-19 vaccine 91.25 percent effective in Turkey trials: CEO

Dateline : Jan 13, 2021/File

Location : Beijing,China

Duration : 2'37

  • English
  • Français


Beijing, China - Jan 13, 2021 (CCTV - No access Chinese mainland)
1. Press conference
2. Reporters
3. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd. (starting with shot 2):
"This vaccine entered Phase I and Phase II clinical studies in April 2020. After confirming the safety and efficacy of the vaccine, we started Phase III clinical studies in Brazil, Turkey, Indonesia, Chile and other countries."
4. Reporters
5. Government officials at press conference
6. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd (partially overlaid with shot 7):
"We have enrolled 24,400 volunteers, finished the overall evaluation work and released the main research data. The interim analysis results for the trials in Turkey showed the vaccine is 91.25 percent effective. The results of Phase III clinical trials in Indonesia showed the vaccine has an efficacy rate of 64.5 percent."
++SHOT OVERLAYING SOUNDBITE++
7. Reporters
++SHOT OVERLAYING SOUNDBITE++
8. Various of reporters
9. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd:
"The Phase III trials in Brazil showed the vaccine is 100 percent effective in preventing severe illness and hospitalization. It is 78 percent effective in preventing medical treatment, and 50.3 percent effective for high-risk groups such as medical workers."

Beijing, China - Recent (CCTV - No access Chinese mainland)
10. Various of Sinovac Biotech workers at workshop, vaccines on producing line

Beijing, China - Jan 13, 2021 (CCTV - No access Chinese mainland)
11. SOUNDBITE (Chinese) Yin Weidong, Chairman of Board and CEO, Sinovac Biotech Ltd:
"As of January 10, more than 7 million doses of inactivated vaccines have been supplied to different provincial-level regions in China, especially Beijing and Guangdong, where large-scale vaccinations have been started, showing good safety of the vaccine. We are still studying and tracking the efficacy rate for the Chinese recipients."

Shanghai, China - Jan 6, 2021 (CCTV - No access Chinese mainland)
12. Various of medical worker registering vaccine recipients' information
13. Medical worker injecting COVID-19 vaccine on man

Beijing, China - Jan 2-6, 2021 (CCTV - No access Chinese mainland)
14. People lining up for vaccination

Shanghai, China - Jan 6, 2021 (CCTV - No access Chinese mainland)
15. Medical worker injecting COVID-19 vaccine on man


The coronavirus vaccine developed by China's Sinovac Biotech is 91.25 percent effective in its Phase III clinical trials in Turkey, Board Chairman and CEO of the company Yin Weidong said in Beijing on Wednesday.

"This vaccine entered Phase I and Phase II clinical studies in April 2020. After confirming the safety and efficacy of the vaccine, we started Phase III clinical studies in Brazil, Turkey, Indonesia, Chile and other countries," Yin said at a press conference.

Yin said the company has finished the overall evaluation of the Phase III trials after enrolling the test results of 24,400 volunteers.

"The interim analysis results for the trials in Turkey showed the vaccine is 91.25 percent effective. The results of Phase III clinical trials in Indonesia showed the vaccine has an efficacy rate of 64.5 percent," he said.

"The Phase III trials in Brazil showed the vaccine is 100 percent effective in preventing severe illness and hospitalization. It is 78 percent effective in preventing medical treatment, and 50.3 percent effective for high-risk groups such as medical workers," said Yin.

He said the vaccine is being widely administered among Chinese citizens.

"As of January 10, more than 7 million doses of inactivated vaccines have been supplied to different provincial-level regions in China, especially Beijing and Guangdong, where large-scale vaccinations have been started, showing good safety of the vaccine. We are still studying and tracking the efficacy rate for the Chinese recipients," Yin said.

ID : 8173471

Published : 2021-01-13 17:58

Last Modified : 2021-01-14 15:58:45

Source : China Central Television (CCTV)

Restrictions : No access Chinese mainland

More



Login
Username
Password
code
Sign In
OK